Chris Lau
1
All posts from Chris Lau
Chris Lau in Value Stocks,

Biotech's Ups and Downs Today: ACAD, RGEN, and More

ACADIA Pharma is attempting a bottom after reporting a quarterly loss and revenue of $4000.

The sales outlook will become clearer. The company finally priced Nuplazid at $1950 a month per patient.

That would translate to $5B revenue, provided it achieves a 50% market penetration.

Regeneron (REGN)

First-quarter results are out for Regeneron. The stock peaked in April and like ACAD, is trying to find a bottom.

Notable: Profits grew 118%. REGN forecasts sales growth in the 20 - 25 percent range. It expects reimbursement from Sanofi at $320M - 370M.

Medivation (MDVN) is on fire. Amgen is reportedly interested in bidding for the company. Now there are four interested parties: Pfizer, AstraZenica, and Sanofi.